Compare Charles River Laboratories Intl. Inc (CRL) vs J B Hunt Transport Services Inc (JBHT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs J B Hunt Transport Services Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $302.47 (market cap $14.23B), while J B Hunt Transport Services Inc trades at $228.12 (market cap $21.45B). The key difference: J B Hunt Transport Services Inc is the larger of the two by market cap, and J B Hunt Transport Services Inc pays a 0.79% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and J B Hunt Transport Services Inc for 45 Days on average.
| CRL | JBHT | |
|---|---|---|
Market Cap | $14.23B | $21.45B |
Volume | 1,176,885 | 1,028,680 |
Sector | Health | Industrials |
52-Week High | $310.77 | $298.41 |
52-Week Low | $149.93 | $137.09 |
Typical Hold Time | 33 Days | 45 Days |
Enterprise Value | $17.06B | $22.59B |
Dividend Yield | — | 0.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $300.53, up 0.08% on the day, with a bullish technical outlook and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, though it faces profitability challenges with a negative net income margin and ROE. Recent investor day presentations highlighted a strategic plan targeting 5-7% revenue growth and $300 million in savings by 2030, driving positive sentiment.
The outlook is cautiously optimistic, supported by analyst buy ratings and a $305.50 consensus price target, but risks include ongoing margin pressure, volatile non-human primate costs, and a high valuation multiple. Earnings growth and successful execution of the new strategic plan are critical for sustained upside.
JBHT trades at $228.99, up 2.85% today, with a bearish technical signal from moving averages and oscillators. The company reported revenue of $12.00B in 2025, with a net income margin of 4.98%, and has beaten EPS estimates in recent quarters. Analyst consensus is a Buy with a $289.40 price target, but news highlights ongoing securities class action investigations.
The outlook is mixed: strong fundamentals and analyst support suggest upside, but technical weakness and legal risks pose headwinds. Investors should weigh earnings growth potential against cost pressures and litigation uncertainties for balanced risk-reward assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About J B Hunt Transport Services Inc
J.B. Hunt Transport Services ranks among the top surface transportation companies in North America by revenue. Its primary operating segments are intermodal delivery, which uses the Class I rail carriers for the underlying line-haul movement of its owned containers (45% of sales in 2021).
Read more on JBHT →
